contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


circio-presents-results-that-further-validate-the-circvec-circular-rna-platform-at-two-international-industry-conferences

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Circio Holding

Oslo, Norway 5 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that...

<div class="abstract">Oslo, Norway 5 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky are presenting updated data demonstrating the significant advantages of Circio's circular RNA circVec platform compared to current mRNA-based vector technology. The data further strengthens the in vitro and in vivo validation of Circio's platform. The presentations are being delivered at two major biopharma industry conferences in Basel, Switzerland, and Stockholm, Sweden.</div>The presentations detail the advantages and potential of the circVec 3.0 generation to improve on current mRNA-based technology for a range of therapeutic applications. In vivo expression data has shown an estimated circRNA half-life of over 600 hours vs. under 10 hours for linear mRNA, which translates to over 70 times prolonged RNA durability and 15 times enhanced protein expression. Novel systemic LNP-delivery data demonstrates robust and durable circVec expression in spleen, far outperforming equivalent mRNA-vectors. This important finding has the potential to open up attractive therapeutic opportunities for the circVec technology in several areas, such as cell therapy. Further experimental work is currently ongoing to validate and characterize these observations. "The recent results showing efficient and specific circVec delivery to spleen are very promising and hints at novel opportunities for our circular RNA platform in cell and immune therapies," said&nbsp; Dr. Victor Levitsky, CSO of Circio. "A broad set of experiments to further investigate this observation, as well as in vivo testing of the novel circVec 3.0 generation, will read out over the next 6-12 weeks. The performance of circVec 3.0-AAV constructs is of particular interest, which we believe has the potential to transform current gold-standard AAV gene therapy and generate substantial partnering interest."See below for titles and presentation materials:<a style="color:blue; text-decoration:underline" href="https://informaconnect.com/rna-leaders-europe/agenda/2/">RNA Leaders Europe Congress</a>&nbsp;&nbsp; Title: Deploying circular RNA expression to boost gene therapy - AAV and beyond Time &amp; place: 5 March 2025, Basel, SwitzerlandPresenter: Dr. Erik Digman Wiklund, CEO <a style="color:blue; text-decoration:underline" href="https://www.imapac.com/events/biologics-world-nordics-2025">Biologics World Nordics 2025</a> Title: CircVec - A Novel Payload Expression Platform Based on Circular RNA Biogenesis: Features and Opportunities Time &amp; place: 5 March 2025, Stockholm, Sweden Presenter: Dr. Victor Levitsky, CSO<div></div>

Circio presents results that further validate the circVec circular RNA platform at two international industry conferences